Medincell Sa Stock Analysis
| MDCLF Stock | USD 6.98 0.00 0.00% |
MedinCell SA has over 16.25 Million in debt which may indicate that it relies heavily on debt financing. MedinCell's financial risk is the risk to MedinCell stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
MedinCell's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. MedinCell's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps MedinCell Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect MedinCell's stakeholders.
For most companies, including MedinCell, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for MedinCell SA, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, MedinCell's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that MedinCell's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which MedinCell is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of MedinCell to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, MedinCell is said to be less leveraged. If creditors hold a majority of MedinCell's assets, the Company is said to be highly leveraged.
MedinCell SA is fairly valued with Real Value of 6.98 and Hype Value of 6.98. The main objective of MedinCell pink sheet analysis is to determine its intrinsic value, which is an estimate of what MedinCell SA is worth, separate from its market price. There are two main types of MedinCell's stock analysis: fundamental analysis and technical analysis.
The MedinCell pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and MedinCell's ongoing operational relationships across important fundamental and technical indicators.
MedinCell |
MedinCell Pink Sheet Analysis Notes
About 48.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.88. MedinCell SA had not issued any dividends in recent years. The entity had 50:1 split on the 16th of March 2017. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception mdc-ANG for CNS related treatments mdc-ELK for depression and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. Medincell is traded on OTC Exchange in the United States.The quote for MedinCell SA is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about MedinCell SA contact Christophe Douat at 33 4 67 02 13 67 or learn more at https://www.medincell.com.MedinCell SA Investment Alerts
| MedinCell SA generated a negative expected return over the last 90 days | |
| The company reported the revenue of 4.09 M. Net Loss for the year was (24.81 M) with profit before overhead, payroll, taxes, and interest of 4.09 M. | |
| MedinCell SA has accumulated about 34.39 M in cash with (21.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38. | |
| Roughly 48.0% of the company outstanding shares are owned by corporate insiders |
MedinCell Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 244.65 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate MedinCell's market, we take the total number of its shares issued and multiply it by MedinCell's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MedinCell SA, as well as the relationship between them.MedinCell SA Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Simple Moving Average indicator is calculated by adding the closing price of MedinCell for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out MedinCell SA short-term fluctuations and highlight longer-term trends or cycles.
MedinCell SA Debt to Cash Allocation
Many companies such as MedinCell, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
MedinCell SA has accumulated 16.25 M in total debt with debt to equity ratio (D/E) of 4.86, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. MedinCell SA has a current ratio of 2.78, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist MedinCell until it has trouble settling it off, either with new capital or with free cash flow. So, MedinCell's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MedinCell SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MedinCell to invest in growth at high rates of return. When we think about MedinCell's use of debt, we should always consider it together with cash and equity.MedinCell Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the MedinCell's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of MedinCell, which in turn will lower the firm's financial flexibility.About MedinCell Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how MedinCell prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling MedinCell shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as MedinCell. By using and applying MedinCell Pink Sheet analysis, traders can create a robust methodology for identifying MedinCell entry and exit points for their positions.
It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception mdc-ANG for CNS related treatments mdc-ELK for depression and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. Medincell is traded on OTC Exchange in the United States.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding MedinCell to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios |
| All Next | Launch Module |
Complementary Tools for MedinCell Pink Sheet analysis
When running MedinCell's price analysis, check to measure MedinCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MedinCell is operating at the current time. Most of MedinCell's value examination focuses on studying past and present price action to predict the probability of MedinCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MedinCell's price. Additionally, you may evaluate how the addition of MedinCell to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |